Difference between revisions of "Cemiplimab (Libtayo)"
Jump to navigation
Jump to search
m (Jwarner moved page Cemiplimab (REGN2810) to Cemiplimab (Libtayo): FDA approval) |
Warner-admin (talk | contribs) m (Text replacement - "Category:Immunotherapy" to "Category:Immunotherapeutic") |
||
| Line 15: | Line 15: | ||
[[Category:Intravenous medications]] | [[Category:Intravenous medications]] | ||
| − | [[Category: | + | [[Category:Immunotherapeutic]] |
[[Category:T-cell activators]] | [[Category:T-cell activators]] | ||
[[Category:Antibody medications]] | [[Category:Antibody medications]] | ||
Revision as of 17:40, 3 February 2019
Mechanism of action
From NCI Drug Dictionary: A human monoclonal antibody directed against the negative immunoregulatory human cell surface receptor programmed cell death 1 (PD-1, PCD-1) protein, with potential immune checkpoint inhibitory and antineoplastic activity. Upon administration, cemiplimab binds to PD-1, inhibits its binding to the PD-1 ligand programmed cell death-1 ligand 1 (PD-L1), and prevents the activation of its downstream signaling pathways.
Diseases for which it is used
History of changes in FDA indication
- 9/28/2018: Initial approval "for patients with metastatic cutaneous squamous cell carcinoma (CSCC) or locally advanced CSCC who are not candidates for curative surgery or curative radiation."
Also known as
- Code name: REGN2810
- Generic name: cemiplimab-rwlc
- Brand name: Libtayo